But a more recently filed consumer class action adds a parallel set of allegations to the litigation landscape, reframing the conflict as one that spans patent law, FDA regulation, pharmaceutical manufacturing, and brand positioning in a market that is both commercially dominant and culturally ubiquitous
The most commonly reported adverse effects in GLP-1 clinical trials include gastrointestinal symptoms such as nausea (occurring in 15-44% of patients depending on the specific agent and dose), vomiting, diarrhea, constipation, and abdominal pain
Current studies are evaluating whether higher doses of oral GLP-1s can close this gap an important development for people who are averse to injections
For your convenience, we have included a fax template that lists common dosing in the Resources for Providers section above
Explore a medically guided GLP-1 program designed for precision and long-term success